Immunotherapy of Gram-negative Bacterial Sepsis

Authors:
  • DDDavid L. Dunn
    David L. Dunn
  • DEDavid C. Ewald
    David C. Ewald
  • NCNaresh Chandan
    Naresh Chandan
  • FCFrank B. Cerra
    Frank B. Cerra

Abstract
• Previous experimental and clinical studies have demonstrated the ability of polyclonal antibody directed against the core lipopolysaccharide (LPS)-lipid A component of endotoxin to reduce mortality. We sought to characterize the ability of a single murine monoclonal IgG, antibody (8A1 MAb) to react to a variety of gram-negative microorganisms, to promote phagocytosis, and to provide protection during experimental murine sepsis. The 8A1 MAb reacted to various gram-negative bacterial whole cell and LPS antigens examined by enzyme-linked immunosorbent assay. Reactivity was highest toSalmonella minnesotaRe LPS and lipid A. Phagocytosis was promoted by this monoclonal antibody to several gram-negative bacteria, exceptPseudomonas aeruginosa.The 8A1 MAb (2 mg per mouse) enhanced survival during bacteremia due to eitherEscherichia coli0111:B4 orKlebsiella pneumoniae, and during endotoxemia due to all types of LPS examined exceptP aeruginosa.We concluded that a single MAb with anti—lipid A specificity was cross reactive in vitro and cross protective in vivo. A clinical trial comparing polyclonal and monoclonal antibody in high-risk septic patients seems warranted. (Arch Surg1986;121:58-62)